Improving medicines adherence with VR

With medicine adherence still a major problem for pharma and healthcare systems, a collaboration between Cognitant Group and Addenbrooke’s Hospital –supported by grants from UCB and Pfizer

Patient voice overcomes EU ‘no’ for UCB/Amgen’s osteoporosis...

UCB/Amgen’s osteoporosis drug Evenity (romosozumab) looks set for approval in Europe after regulators finally recommended it, following a successful appeal against a rejection with help fro

UCB’s bimekizumab tops J&J’s Stelara in psoriasis study

UCB sets sights on rare diseases giant Alexion with Ra Pharm...

UCB is to buy US biotech Ra Pharma in a deal worth around $2.1 billion, adding a late-stage treatment for the rare muscle weakness disease myasthenia gravis to its R&D pipeline and sett

CHMP says no to Amgen’s osteoporosis drug Evenity

At long last, Amgen/UCB score FDA okay for Evenity

Amgen and UCB finally have FDA approval for osteoporosis drug Evenity, two years after it was turned down by the regulator because of safety concerns.